Comparative Pharmacology
Head-to-head clinical analysis: CICLOPIROX versus FUNGIZONE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CICLOPIROX versus FUNGIZONE.
CICLOPIROX vs FUNGIZONE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ciclopirox is a hydroxypyridone antifungal agent that chelates polyvalent metal cations (e.g., Fe3+, Al3+) inhibiting metal-dependent enzymes, thereby disrupting fungal cellular metabolic processes, including mitochondrial electron transport and energy production.
Binds to ergosterol in fungal cell membranes, forming pores that increase permeability, leading to leakage of intracellular contents and cell death.
Ciclopirox 8% nail lacquer: Apply to affected nails once daily for up to 48 weeks. Ciclopirox 1% cream or lotion: Apply to affected skin twice daily for 2-4 weeks. Ciclopirox 1% shampoo: Apply to wet hair, lather, leave for 3 minutes, rinse; use twice weekly for 4 weeks (for seborrheic dermatitis).
IV: 0.25-1 mg/kg/day as a single infusion; for aspergillosis, up to 1.5 mg/kg/day; maximum daily dose 1.5 mg/kg.
None Documented
None Documented
Clinical Note
moderateCiclopirox + Tranilast
"The risk or severity of adverse effects can be increased when Ciclopirox is combined with Tranilast."
Clinical Note
moderateCiclopirox + Tolfenamic acid
"The risk or severity of adverse effects can be increased when Ciclopirox is combined with Tolfenamic acid."
Clinical Note
moderateCiclopirox + Nimesulide
"The risk or severity of adverse effects can be increased when Ciclopirox is combined with Nimesulide."
Clinical Note
moderateCiclopirox + Risedronic acid
Terminal elimination half-life: 1.7-3.0 hours in healthy individuals; prolonged in hepatic impairment
Terminal elimination half-life is approximately 15 days (range 10-20 days) after a single dose; with prolonged therapy, a prolonged terminal half-life of up to 15 days reflects slow redistribution from tissue depots.
Renal: approximately 70-80% of the absorbed dose as unchanged drug and glucuronide conjugates; biliary/fecal: ~20-30%
Primarily fecal (40-50%) via biliary elimination without metabolism; renal excretion of unchanged drug is minimal (<5% in 24 hours).
Category A/B
Category C
Antifungal
Antifungal
"The risk or severity of adverse effects can be increased when Ciclopirox is combined with Risedronic acid."